Form 10-Q Summary
Filing identity: The provided filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. It covers the unaudited quarter ended March 31, 2013 and was filed May 15, 2013.
Business Context and Reporting Period
Zeta Acquisition Corp. II was a Delaware development-stage blank-check and shell company incorporated in 2007 to identify and complete a business combination with an operating company. It had no operating business, generated no revenue, and had not identified or engaged in discussions with a potential target as of the filing date. The company reported 5,000,000 common shares outstanding as of May 15, 2013.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2013 | Comparable Period / Other |
|---|---|---|
| Revenue | $0 | $0 since inception |
| Operating expenses | $4,806 | $4,231 in Q1 2012 |
| Interest expense | $1,257 | $1,131 in Q1 2012 |
| Net loss | $6,063 | $5,362 in Q1 2012 |
| Net loss per share | $0.00 loss per basic and diluted share | $0.00 loss in Q1 2012 |
| Cash used in operating activities | $1,901 | $5,527 used in Q1 2012 |
| Cash provided by financing activities | $0 | $25,000 in Q1 2012 |
| Cash and cash equivalents | $2,706 at March 31, 2013 | $4,607 at December 31, 2012 |
| Total assets | $3,831 | $8,107 at December 31, 2012 |
| Total liabilities | $105,435 | $103,648 at December 31, 2012 |
| Stockholders’ deficit | $101,604 | $95,541 at December 31, 2012 |
Since inception, the company reported an accumulated net loss of $151,604 and cumulative net cash used in operating activities of $132,294. Current liabilities included $85,000 of unsecured notes payable to stockholders and $12,555 of accrued interest.
Material Changes Versus the Prior Comparable Period
- Net loss increased to $6,063 from $5,362, primarily reflecting higher general and administrative expenses and interest expense.
- Cash used in operating activities improved to $1,901 from $5,527, partly because of changes in prepaid expenses, accounts payable, and accrued expenses.
- Q1 2013 included no financing proceeds, compared with $25,000 of stockholder loan proceeds in Q1 2012.
- Cash declined by $1,901 during Q1 2013, from $4,607 to $2,706.
- Total assets declined by $4,276 from December 31, 2012, while total liabilities increased by $1,787.
Outlook, Liquidity, Risks, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC reporting and acquisition investigations. The company expected to fund operations through existing cash, deferred fees, and additional loans or investments from stockholders, management, or other investors. No assurance was provided that additional funding would be available.
Management stated that the company’s ability to continue as a going concern depends on obtaining financing, generating future profitable operations, and completing a suitable business combination. The financial statements were prepared on a going-concern basis and did not include adjustments that might be required if the company could not continue operating.
The company had no revenues, no material off-balance-sheet arrangements, and no material pending legal proceedings. Office space and equipment were provided by an officer and director at no cost on a month-to-month basis, with estimated value described as de minimis. The company also disclosed that it was a smaller reporting company and emerging growth company and had elected the JOBS Act extended transition period for certain accounting standards.
Management concluded that disclosure controls and procedures were effective as of March 31, 2013, with no material changes to internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer identity: the filing names Zeta Acquisition Corp. II, whereas the request identifies Whitehawk Therapeutics, Inc.
- Verify the company’s shell and blank-check status and whether any subsequent business combination occurred.
- Assess the going-concern risk given only $2,706 of cash against $105,435 of current liabilities.
- Review the terms, maturity, related-party status, and interest obligations of the $85,000 stockholder notes.
- Confirm whether additional related-party financing or equity financing was obtained after March 31, 2013.
- Review subsequent filings for changes in ownership, corporate name, business purpose, or operating status.